Suppression of de novo lipogenesis via FA synthase (FASN) inhibition was shown to attenuate CD44 expression, possibly through its palmitoylation [[72], [73], [74]], highlighting the association between lipid metabolism and cancer stemness. The gene discussed is CD44; the disease is cancer.